Mirum Pharmaceuticals: Results Available from PBC and PSC Studies on Volixibat
source: shutterstock.com

Mirum Pharmaceuticals: Results Available from PBC and PSC Studies on Volixibat

Mirum Pharmaceuticals has long been a leader in the rare liver disease space, driving forward with a mission of empowering patients and families, and identifying novel therapeutic interventions to help…

Continue Reading Mirum Pharmaceuticals: Results Available from PBC and PSC Studies on Volixibat

RECAP: My Time at the PBCers 2024 Patient Education Conference: “Empowering Connections in PBC”

What’s better than being in warm and sunny Arizona? Getting to learn alongside the amazing primary biliary cholangitis (PBC) community while there! The PBCers organization held its 2024 Patient Education…

Continue Reading RECAP: My Time at the PBCers 2024 Patient Education Conference: “Empowering Connections in PBC”
Obeticholic Acid – Bezafibrate Combination Granted Orphan Drug Designation for Primary Biliary Cholangitis (PBC)
source: pixabay.com

Obeticholic Acid – Bezafibrate Combination Granted Orphan Drug Designation for Primary Biliary Cholangitis (PBC)

  In mid-May 2023, Pharmaceutical Technology reported that a new combination treatment had earned Orphan Drug designation. This combo? Obeticholic acid (OCA) and bezafibrate. Together, they represent a potential therapeutic…

Continue Reading Obeticholic Acid – Bezafibrate Combination Granted Orphan Drug Designation for Primary Biliary Cholangitis (PBC)
Obeticholic Acid Resolves Cognitive Deficits from Primary Biliary Cholangitis
source: pixabay.com

Obeticholic Acid Resolves Cognitive Deficits from Primary Biliary Cholangitis

  Cognitive deficits have been recognized as symptoms of advanced liver disease for many years. As reported in Bioengineer, the American Journal of Pathology recently published a study providing insights…

Continue Reading Obeticholic Acid Resolves Cognitive Deficits from Primary Biliary Cholangitis
The First Patient has Been Dosed in a Clinical Trial for Primary Biliary Cholangitis Treatment
source: pixabay.com

The First Patient has Been Dosed in a Clinical Trial for Primary Biliary Cholangitis Treatment

Gannex has just announced that they have dosed the first patient in their Phase 2 clinical trial examining ASC42 as a treatment for those diagnosed with primary biliary cholangitis (PBC).…

Continue Reading The First Patient has Been Dosed in a Clinical Trial for Primary Biliary Cholangitis Treatment
Phase 1 Trial for Primary Biliary Cholangitis Therapy Produces Promising Results
source: pixabay.com

Phase 1 Trial for Primary Biliary Cholangitis Therapy Produces Promising Results

Albireo Pharma Inc. has just announced the results from their Phase 1 clinical trial for A3907, an ASBT inhibitor. The study produced positive results, achieving its primary and secondary endpoints. Researchers…

Continue Reading Phase 1 Trial for Primary Biliary Cholangitis Therapy Produces Promising Results
Research in Treatment Options for Primary Biliary Cholangitis (PBC)
Happy mature woman looking at friend in forest. Female friends are sitting at lakeshore. They are communicating in woodland.

Research in Treatment Options for Primary Biliary Cholangitis (PBC)

Acknowledgment: This story is sponsored by CymaBay Therapeutics and is promoted through the Patient Worthy Collaborative Content program. We only publish content that embodies our mission of providing relevant, vetted and valuable information…

Continue Reading Research in Treatment Options for Primary Biliary Cholangitis (PBC)

Positive Topline Data Available on A3907 for Cholestatic Liver Diseases

In a news release from mid-December 2021, rare liver disease company Albireo Pharma, Inc. ("Albireo") shared that positive topline data was available from a Phase 1 clinical trial evaluating A3907…

Continue Reading Positive Topline Data Available on A3907 for Cholestatic Liver Diseases
Initiation of Global Phase 3 Trial of Alagille Syndrome Treatment
source: pixabay.com

Initiation of Global Phase 3 Trial of Alagille Syndrome Treatment

Albireo has recently initiated their Phase 3 ASSERT trial, according to GlobeNewswire. This study will evaluate odevixibat as a treatment for Alagille syndrome. This therapy fits well with Albireo's mission,…

Continue Reading Initiation of Global Phase 3 Trial of Alagille Syndrome Treatment

CymaBay Therapeutics Announces Results of Global Phase 3 ENHANCE Study for Primary Biliary Cholangitis

CymaBay Therapeutics, a biopharmaceutical company based in Newark, CA, develops and provides access to novel therapies with a recent focus on primary biliary cholangitis (PBC). The company is currently developing…

Continue Reading CymaBay Therapeutics Announces Results of Global Phase 3 ENHANCE Study for Primary Biliary Cholangitis
ICYMI: Study of Primary Biliary Cholangitis Treatment Shows Positive Results
source: pixabay.com

ICYMI: Study of Primary Biliary Cholangitis Treatment Shows Positive Results

CymaBay Therapeutics has recently released the results from ENHANCE, a study of seladelpar as a treatment for primary biliary cholangitis (PBC). These results were positive, proving that this medication has…

Continue Reading ICYMI: Study of Primary Biliary Cholangitis Treatment Shows Positive Results
The Results from a Primary Biliary Cholangitis Trial Look Promising
source: pixabay.com

The Results from a Primary Biliary Cholangitis Trial Look Promising

According to a story from GlobeNewswire, the biopharmaceutical company CymaBay Therapeutics, Inc. recently announced encouraging topline findings from a phase 3 clinical trial. This study was testing seladelpar as a…

Continue Reading The Results from a Primary Biliary Cholangitis Trial Look Promising
Study Finds That Denosumab can Boost Bone Density in Primary Biliary Cholangitis and Autoimmune Hepatitis
Free-Photos / Pixabay

Study Finds That Denosumab can Boost Bone Density in Primary Biliary Cholangitis and Autoimmune Hepatitis

According to a story from Healio, a recent study has illustrated that the drug denosumab can improve the bone density of patients with primary biliary cholangitis (PBC) and autoimmune hepatitis…

Continue Reading Study Finds That Denosumab can Boost Bone Density in Primary Biliary Cholangitis and Autoimmune Hepatitis
Experimental Treatment for Primary Biliary Cholangitis Earns Orphan Drug Status in the US and EU
Aymanejed / Pixabay

Experimental Treatment for Primary Biliary Cholangitis Earns Orphan Drug Status in the US and EU

According to a story from Markets Insider, the biopharmaceutical company GENFIT recently announced that both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have awarded…

Continue Reading Experimental Treatment for Primary Biliary Cholangitis Earns Orphan Drug Status in the US and EU

FDA Clears Phase 2 Trial for Possible Idiopathic Pulmonary Fibrosis Drug

According to a story from BioPortfolio, the biopharmaceutical company Genkyotex has recently announced that the US Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application.…

Continue Reading FDA Clears Phase 2 Trial for Possible Idiopathic Pulmonary Fibrosis Drug